Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL3 | P58215 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.47 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1992198 | 0.86 | ALDH1A1 (0.50) | LOXL3LOXL2HTTPDE7APDE7B | |
| SCHEMBL5431810 | 0.86 | KIF11 (0.47) | LOXL3LOXL2HTTPDE7APDE7B | |
| SCHEMBL5425840 | 0.81 | ALDH1A1 (0.59) | LOXL3LOXL2HTTPDE7APDE7B | |
| SCHEMBL18239987 | 0.77 | PDE7A (0.77) | HTTPDE7APDE7BRXFP1PPARG | |
| SCHEMBL31419817 | 0.77 | PDE7A (0.77) | HTTPDE7APDE7BRXFP1PPARG | |
| SCHEMBL1991634 | 0.73 | HPGD (0.45) | LOXL3LOXL2HTTPDE7APDE7B | |
| SCHEMBL11867641 | 0.73 | PARP1 (0.47) | LOXL3LOXL2PDE7APDE7BHPGD | |
| Hydrochloric Acid SCHEMBL1995732 | 0.71 | HPGD (0.43) | LOXL3LOXL2RXFP1PPARGNPSR1 | |
| SCHEMBL23045531 | 0.69 | ALDH1A1 (0.71) | HTTPDE7APDE7BRXFP1CA12 | |
| SCHEMBL12681731 | 0.69 | CA12 (0.69) | HTTPDE7APDE7BRXFP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759361-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2061794-B1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORP (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-8003656-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100008866-A1 | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES | NEUROGEN CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100008866-A1 | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES | PIGS, GPR174, GPR17 | LOXL3 1320/4885LOXL2 1129/4885HTT 1738/4885 |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | GPR174, GPR17, PTGFR | LOXL3 1019/4885LOXL2 596/4885HTT 2063/4885 |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | GPR174, GPR17, PTGFR | LOXL3 1019/4885LOXL2 596/4885HTT 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.